BRTX
Price
$1.61
Change
-$0.00 (-0.00%)
Updated
Oct 15, 11:04 AM (EDT)
Capitalization
12.84M
33 days until earnings call
Intraday Buy/Sell Signals
CDXS
Price
$2.63
Change
+$0.11 (+4.37%)
Updated
Oct 15, 11:14 AM (EDT)
Capitalization
227.47M
14 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

BRTX vs CDXS

Header iconBRTX vs CDXS Comparison
Open Charts BRTX vs CDXSBanner chart's image
BioRestorative Therapies
Price$1.61
Change-$0.00 (-0.00%)
Volume$300
Capitalization12.84M
Codexis
Price$2.63
Change+$0.11 (+4.37%)
Volume$623
Capitalization227.47M
BRTX vs CDXS Comparison Chart in %
BRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BRTX vs. CDXS commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRTX is a Hold and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (BRTX: $1.61 vs. CDXS: $2.52)
Brand notoriety: BRTX and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BRTX: 34% vs. CDXS: 52%
Market capitalization -- BRTX: $12.84M vs. CDXS: $227.47M
BRTX [@Biotechnology] is valued at $12.84M. CDXS’s [@Biotechnology] market capitalization is $227.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BRTX’s FA Score shows that 1 FA rating(s) are green whileCDXS’s FA Score has 1 green FA rating(s).

  • BRTX’s FA Score: 1 green, 4 red.
  • CDXS’s FA Score: 1 green, 4 red.
According to our system of comparison, both BRTX and CDXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BRTX’s TA Score shows that 5 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • BRTX’s TA Score: 5 bullish, 5 bearish.
  • CDXS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BRTX and CDXS are a good buy in the short-term.

Price Growth

BRTX (@Biotechnology) experienced а -0.62% price change this week, while CDXS (@Biotechnology) price change was -1.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

BRTX is expected to report earnings on Nov 18, 2025.

CDXS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($227M) has a higher market cap than BRTX($12.8M). BRTX YTD gains are higher at: 12.587 vs. CDXS (-47.170). BRTX has higher annual earnings (EBITDA): -12.89M vs. CDXS (-52.78M). CDXS has more cash in the bank: 66.3M vs. BRTX (7.38M). BRTX has less debt than CDXS: BRTX (42.4K) vs CDXS (69M). CDXS has higher revenues than BRTX: CDXS (57.2M) vs BRTX (605K).
BRTXCDXSBRTX / CDXS
Capitalization12.8M227M6%
EBITDA-12.89M-52.78M24%
Gain YTD12.587-47.170-27%
P/E RatioN/AN/A-
Revenue605K57.2M1%
Total Cash7.38M66.3M11%
Total Debt42.4K69M0%
FUNDAMENTALS RATINGS
BRTX vs CDXS: Fundamental Ratings
BRTX
CDXS
OUTLOOK RATING
1..100
2313
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5658
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BRTX's Valuation (29) in the null industry is in the same range as CDXS (32) in the Chemicals Specialty industry. This means that BRTX’s stock grew similarly to CDXS’s over the last 12 months.

BRTX's Profit vs Risk Rating (100) in the null industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that BRTX’s stock grew similarly to CDXS’s over the last 12 months.

BRTX's SMR Rating (99) in the null industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that BRTX’s stock grew similarly to CDXS’s over the last 12 months.

BRTX's Price Growth Rating (56) in the null industry is in the same range as CDXS (58) in the Chemicals Specialty industry. This means that BRTX’s stock grew similarly to CDXS’s over the last 12 months.

BRTX's P/E Growth Rating (100) in the null industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that BRTX’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BRTXCDXS
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APPIF10.44N/A
N/A
APPIER GROUP INC.
RICOY9.15N/A
N/A
Ricoh Company Ltd.
RSAU0.28N/A
N/A
Rooshine Inc.
PSKOF23.75N/A
N/A
ORLEN SA
CSLMF14.00N/A
N/A
CSLM Acquisition Corp.

BRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BRTX has been loosely correlated with TCRT. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if BRTX jumps, then TCRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BRTX
1D Price
Change %
BRTX100%
+0.62%
TCRT - BRTX
33%
Loosely correlated
+5.52%
RLAY - BRTX
29%
Poorly correlated
-3.99%
CERO - BRTX
29%
Poorly correlated
-14.71%
GRCE - BRTX
28%
Poorly correlated
+0.84%
CDXS - BRTX
28%
Poorly correlated
+0.80%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.80%
DNLI - CDXS
50%
Loosely correlated
+1.34%
PRAX - CDXS
48%
Loosely correlated
+0.34%
BEAM - CDXS
48%
Loosely correlated
+0.12%
IPSC - CDXS
47%
Loosely correlated
+1.84%
RXRX - CDXS
45%
Loosely correlated
+6.51%
More